Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25

Benzinga · 1d ago
Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.